In this chapter of Business of Biotech episode 252, Alnylam Chief Commercial Officer Tolga Tanguler shares on the company's strategy to pivot its RNAi therapeutic applications from rare to large ...

Tolga Tanguler, EVP and Chief Commercial Officer at Alnylam Pharmaceuticals, discusses the global opportunity for the commercialization of RNAi therapies with host Ben Comer. Catch the full episode ...

Sometimes the key to making a breakthrough in research, in any field, is to look at the problem differently than anybody has ...

Fear of change is a key limiting factor that is slowing the adoption and value of AI across life sciences. It doesn't have to ...

Cuts to federal research funding at universities and research organizations are pushing academic scientists into life ...

BIO was as busy as ever in Boston this year. With more to come soon, here are a few initial thoughts on three events I ...

Proper legal structuring is essential when it comes to transferring Chinese biotech intellectual property and clinical assets to form a U.S.-based 'Newco,' explain experts at Orrick.

<p>On this week&#39;s episode of the Business of Biotech, Tom Wells, Director of Life Sciences at 4C Associates, reveals why -- and how -- smart procurement practices can make or break emerging ...

The biopharma industry is rapidly evolving. As such, biopharma companies are facing a variety of operational challenges stemming from a high volume of siloed data coupled with regulatory scrutiny that ...

For more than two decades, the EU has pledged numerous initiatives aimed at creating regulatory environments to foster both innovation and investment in the EU’s biotech sector, a sector which broadly ...

A primary industry concern regarding the Joint Clinical Assessment (JCA) and Project Orbis has been the risk of faster price erosion from International Reference Pricing (IRP). However, a new ...